Targovax announces two posters at the 2021 Society for Immunotherapy of Cancer (SITC) Annual Meeting
Oslo, Norway, 9 November 2021 - Targovax ASA (OSE: TRVX), a clinical stage immuno-oncology company developing immune activators to target hard-to-treat solid tumors, today announces that the posters being presented at the Society for Immunotherapy of Cancer (SITC) Annual Meeting now are available at the Company’s website.Both posters are scheduled for presentation 13 November 2021 at the SITC congress. Poster A randomised open-label phase I/II study adding ONCOS-102 totitle: pemetrexed/cisplatin in patients with unresectable malignant pleural mesothelioma – 24-